Mona Munteanu is a full-time employee of Biopredictive.
Steatohepatitis/Metabolic Liver Disease
Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease†
Article first published online: 14 AUG 2008
Copyright © 2008 American Association for the Study of Liver Diseases
Volume 49, Issue 1, pages 97–105, January 2009
How to Cite
Naveau, S., Gaudé, G., Asnacios, A., Agostini, H., Abella, A., Barri-Ova, N., Dauvois, B., Prévot, S., Ngo, Y., Munteanu, M., Balian, A., Njiké-Nakseu, M., Perlemuter, G. and Poynard, T. (2009), Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology, 49: 97–105. doi: 10.1002/hep.22576
Potential conflict of interest: Thierry Poynard is the inventor of the FibroTest with a capital interest in Biopredictive the company marketing FibroTest, the royalties belonging to the French public organization Assistance Publique Hôpitaux de Paris.
- Issue published online: 28 DEC 2008
- Article first published online: 14 AUG 2008
- Accepted manuscript online: 14 AUG 2008 12:00AM EST
- Manuscript Accepted: 7 AUG 2008
- Manuscript Received: 4 MAR 2008
FibroTest has been validated as a biomarker of fibrosis in patients with chronic viral hepatitis, with a similar prognostic value as biopsy. The aim of the study was to compare the diagnostic and prognostic values of FibroTest versus the recently patented biomarkers, FibrometerA, and Hepascore. A total of 218 consecutive patients with ALD and available liver biopsy examination were included. Biomarkers were compared using univariate area under the ROC curves (AUROC) and multivariate analysis (logistic regression and Cox). The median follow-up was 8.2 years. Eighty-five patients died, including 42 deaths related to liver complications. The diagnostic values of FibrometerA and Hepascore did not differ from that of FibroTest for advanced fibrosis (all AUROC = 0.83 ± 0.03) and cirrhosis (FibroTest and FibrometerA = 0.94 ± 0.02, Hepascore = 0.92 ± 0.02), and were significantly greater than those of nonpatented biomarkers (APRI, Forns, FIB4; P < 0.01). In multivariate analysis the most significant was FibroTest (P = 0.001), without independent diagnostic value for FibrometerA (P = 0.19), and Hepascore (P = 0.40). The prognostic values of FibroTest (AUROC for survival or non liver disease-related death = 0.79 ± 0.04), FibrometerA (0.80 ± 0.04), Hepascore (0.78 ± 0.04), did not differ from that of biopsy fibrosis staging (0.77 ± 0.04). In multivariate analysis the most significant were FibroTest (P = 0.004) and biopsy (P = 0.03), without independent prognostic values for FibrometerA (P = 0.41) and Hepascore (P = 0.28). In patients with alcoholic liver disease, FibrometerA and Hepascore did not improve the diagnostic and prognostic values of FibroTest. (HEPATOLOGY 2009;49:97-105.)